EP456: Advice to Pharma at the Intersection of Product Value, Reputation, and Patient Affordability, With Brian Reid

In this comprehensive episode, host Stacey Richter sits down with Brian Reid to discuss pivotal aspects for the pharmaceutical industry. Key topics include understanding product value from the perspectives of plan sponsors, patients, and society, and the significance of benefit design in improving patient affordability. The discussion delves into the complexities of drug pricing, the roles of Pharmacy Benefit Managers (PBMs) and brokers, and the impact of healthcare consolidation on costs. Reid emphasizes the importance of transparent communication among stakeholders, the detrimental effects of cost containment strategies, and the necessity of considering policy and reputational impacts. Throughout the conversation, examples such as the Hepatitis C drug illustrate the broader implications on drug access and affordability. Listeners are provided with critical insights into how pharmaceutical companies can better engage with ultimate purchasers to ensure patients receive necessary, cost-effective treatment.

WHAT YOU'LL LEARN

✅ How to think about "value" in pharma from the perspectives of plan sponsors, patients, and society all at once

✅ Why benefit design plays such a significant role in patient affordability, and what the Kaiser Employer Health Benefits Survey reveals about it

✅ Why pharma needs to showcase its value even when PBMs are often "locked in" at the moment of a formulary decision

✅ Why Brian is celebrating companies that put their prices directly in their press releases

✅ Why hospital monopoly behavior and healthcare consolidation are just as relevant to pharma's affordability conversation as PBM contracting is

WHY THIS MATTERS

Reid's core argument: pharma has an obligation to explain its value — not just claim it — to plan sponsors, patients, and society simultaneously. Transparent communication among stakeholders, not just clever positioning, is what actually improves patient access to necessary, cost-effective drugs, as the Hepatitis C example discussed in the show makes clear.

MENTIONED IN THIS EPISODE

EP300 with Bruce Rector, MD: Apple Podcasts | Spotify | Other Apps

EP448 (Part 1) with Shawn Gremminger: Apple Podcasts | Spotify | Other Apps

EP426 with Nina Lathia, RPh, MSc, PhD: Apple Podcasts | Spotify | Other Apps

EP370 with Erik Davis and Autumn Yongchu: Apple Podcasts | Spotify | Other Apps

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

🔗 Healthcare Industry Acronyms and Terms

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

📺 Subscribe to our YouTube channel

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

08:29 Why is it important to understand the term "value" in respect to medicine?

10:07 Why is it important to consider all the players affected by the idea of this "value"?

11:06 Who are the ultimate purchasers in Pharma?

12:23 Findings of the Kaiser Employer Health Benefits Survey.

14:52 Why does it matter that we consider what value looks like to all players affected by Pharma?

20:04 What does Pharma need to do to showcase their value when PBMs are often "locked in" at the moment?

23:11 Why Brian is celebrating companies that put their prices in their press releases.

32:31 Why does Pharma have an obligation to explain their value?

33:39 Why is it important for Pharma to keep an eye on hospital monopoly behavior?

37:44 Why Pharma needs to capitalize on alignment.